InnoCare Pharma (9969) Q4 2025 earnings summary

Executive summary

• Achieved first annual profitability in 2025, with net profit of RMB 644.2 million, reversing a prior loss and driven by 135% year-over-year revenue growth, strong drug sales, and global licensing revenue.

• Total revenue reached RMB 2.38 billion, with drug sales up 43% to RMB 1.44 billion, led by orelabrutinib and tafasitamab launches.

• Advanced internationalization strategy through major licensing deals and strategic collaborations, unlocking over $2.5 billion in potential deal value and expanding global presence.

• Significant progress in oncology, autoimmune, and solid tumors, with multiple regulatory approvals, late-stage clinical advancements, and global expansion.

• Maintained robust cash reserves, supporting ongoing R&D and global expansion.

Financial highlights

• Net profit reached RMB 644.2 million, marking the first profitable year, with diluted EPS of RMB 0.38.

• Total revenue for 2025 was RMB 2.38 billion, up 135% year-over-year; drug sales grew 43% to RMB 1.44 billion.

• R&D expenses rose 16.9% to RMB 952 million, focused on late-stage clinical programs and new platforms.

• Cash and related balances at year-end were RMB 7.8 billion, with positive operating cash flow achieved for the first time.

• Gross profit increased 150.7% to RMB 2,183.8 million, with gross margin rising to 92.0%.

Outlook and guidance

• Drug sales expected to grow by more than 35% in 2026, driven by new indications and expanded hospital coverage.

• Multiple major data readouts and NDA submissions anticipated in 2026, including for Mesutoclax, Soficitinib, and ICP-488.

• Management anticipates 2026 to be catalyst-rich, with accelerated revenue growth, improved operating leverage, and enhanced earnings visibility.

• R&D expenses projected to grow around 20% in 2026, with no near-term financing pressure.

• Continued focus on globalization, selective out-licensing, and regional partnerships to maximize asset value.